Bupivacaine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Bupivacaine: From Local Anesthesia to Acrodermatitis Chronica Atrophicans
One-Sentence Summary
Bupivacaine is a well-known local anesthetic/analgesic agent (voltage-gated sodium channel blocker), though its Norway-approved indication text is not present in this evidence pack. The TxGNN model predicts it may be effective for Acrodermatitis Chronica Atrophicans, a late-stage skin manifestation of Lyme disease, but no clinical trials and no publications currently support this direction — the model's own rationale flags the mechanistic link as unsupported.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in registry data (drug class per evidence pack: local anesthesia/regional analgesia); no Norway-approved indication text available |
| Predicted New Indication | Acrodermatitis Chronica Atrophicans |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L5 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form (original_moa is flagged as a data gap). Based on the rationale text accompanying this prediction, Bupivacaine is a voltage-gated sodium channel blocker whose known pharmacological effect is local anesthesia/analgesia.
Acrodermatitis chronica atrophicans is a chronic, atrophic skin manifestation of late-stage Lyme disease (Borrelia infection), pathologically driven by chronic spirochetal infection, immune response, and abnormal collagen metabolism. There is no known pharmacological overlap between sodium-channel blockade (Bupivacaine's mechanism) and the infectious/immune/fibrotic pathways underlying this condition.
The evidence pack's own rationale explicitly states that this high TxGNN score likely reflects an indirect knowledge-graph association (e.g., co-occurrence with other dermatology drugs) rather than a genuine mechanistic link. No direct pharmacological rationale supports this repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Currently no marketed authorizations in Norway (market status: Not Marketed; 0 licenses on record)
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical or literature evidence supporting this indication, and the evidence pack's own mechanistic analysis flags the predicted association as lacking pharmacological plausibility (likely a knowledge-graph co-occurrence artifact). The drug is also not currently marketed in Norway, and safety documentation is incomplete.
To proceed, the following is needed:
- TFDA/Norway product label warnings and contraindications (blocking data gap — required before any S1 safety review)
- Confirmed original mechanism of action and approved indication text (currently a data gap)
- Preclinical or mechanistic studies establishing a plausible biological link to acrodermatitis chronica atrophicans before further evaluation
- Re-screening of lower-ranked candidates (neonatal dermatomyositis, secondary ILD in childhood connective tissue disease, amyopathic dermatomyositis) — all similarly lack mechanistic or evidentiary support and carry the same Hold recommendation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.